OPHTHALMIC DRUGS MARKET ANALYSIS

Regional Analysis

Global Ophthalmic Drugs Market: Regional Insights

Based on geography, the global ophthalmic drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Among regions, North America is expected to gain highest share in the market during the forecast period owing to the increasing prevalence of ophthalmic disorders, growing geriatric population, and growing research and development pertaining to the development of novel drugs in the region. For instance, According to the Centers for Disease Control and Prevention (CDC), more than 4.2 million people in the U.S. aged 40 years and more are either legally blind or are with low vision. The leading causes of blindness and low vision in the U.S. are primarily age-related eye diseases such as cataract, glaucoma, diabetic retinopathy, and age-related macular degeneration.

Asia Pacific is also expected to witness robust growth in the global ophthalmic drugs market due to the growing prevalence of eye-related disorders, increasing geriatric population, and increase in demand for ophthalmic drugs in the region. For instance, glaucoma, cataracts, diabetic retinopathy, and macular degeneration are the four most common eye conditions among people over age 65. According to the United Nations Population Fund (UNPF), the number of elderly people in Asia-Pacific is expected to more than quadruple by 2050, increasing from 630 million in 2020 to over 1.3 billion. This in turn is expected to drive the market growth.

• North America: U.S. and Canada
• Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
• Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
• Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
• Middle East and Africa: GCC Countries, Israel, Rest of Middle East, South Africa, North Africa, and Central Africa